Advertisement

Topics

Immunomic Therapeutics, Inc.(ITI) Company Profile

08:45 EDT 22nd April 2018 | BioPortfolio

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax for use in the prevention and treatment of allergic diseases which resulted in over $350M in licensing revenue that year, the company has now focused on the application of LAMP technology in oncology. For information about ITI and LAMP Technology, visit www.immunomix.com.


News Articles [705 Associated News Articles listed on BioPortfolio]

Immunomic CEO to Speak at 2018 BioHealth Capital Region Forum

Panel Will Discuss Strengths in BioHealth Immunotherapies Immunomic Therapeutics, Inc. (ITI) CEO Bill Hearl, Ph.D., will participate in a panel discussion on immunotherapy at ...

Immunomic Scientist Dr. Pratima Sinha to Speak at the International Conference on Vaccine Research and Development

Presentation to Examine the Potential of LAMP Enhancing Antitumor Immunity Tomorrow, Immunomic Therapeutics, Inc. scientist, Dr. Pratima Sinha, will present at the 3rd ...

Immunomic Therapeutics’ Founder Appointed to Maryland Life Sciences Advisory Board

Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company is pleased to announce Immunomic's founder and CEO, William Hearl, Ph.D., has been appoi...

ITI Senior Director of Corporate Development to Participate in an All Women’s Leadership Panel Discussion and Dinner at ISPE’s First Women in Pharma Event

Immunomic Therapeutics, Inc. Senior Director of Corporate Development Sia Anagnostou will participate in ISPE’s first Women in Pharma Event in Gaithersburg, MD. The panel will c...

ITI Senior Director of Corporate Development to Present on LAMP-Vax Investigational Technology at Immuno-Oncology Frontiers World

Tomorrow, Immunomic Therapeutics, Inc. Senior Director of Corporate Development Sia Anagnostou will present at Phacilitate’s Immuno-Oncology Frontiers World in Miami. The presen...

Dr. Duane Mitchell Reports Findings of Study Aimed at Aggressive Brain Cancer

Cancer Vaccination Approach Incorporates Immunomic Therapeutics' LAMP-Vax Technology with CMV Technology Last week results from a study conducted by investigators in the ...

Immunomic to Participate at 2018 BIO CEO & Investor Conference with Presentation and Panel Discussion

Immuno-Oncology Panel led by Scientific American Immunomic Therapeutics (ITI), pioneering the study of investigational LAMP-based nucleic acid immunotherapy programs, announce...

Immunomic Therapeutics Welcomes Key Thought Leader in Immuno-Oncology, Dr. Drew Pardoll, to Its Scientific Advisory Board

Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, is pleased to welcome Drew Pardoll, MD, Ph.D., Director of the Bloomberg~Kimmel Institu...

PubMed Articles [416 Associated PubMed Articles listed on BioPortfolio]

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Eyes on New Product Development: Preclinical Research.

Eyes on New Product Development: Preclinical Research.

Introduction to Volume 1 of JOPT Special Issue.

Clinical Trials [139 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1214 Associated Companies listed on BioPortfolio]

Immunomic Therapeutics, Inc.(ITI)

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These inve...

Immunomic Therapeutics (ITI)

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These i...

Immunomic Therapeutics, Inc. (ITI)

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing ne...

Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing ne...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

More Information about "Immunomic Therapeutics, Inc.(ITI)" on BioPortfolio

We have published hundreds of Immunomic Therapeutics, Inc.(ITI) news stories on BioPortfolio along with dozens of Immunomic Therapeutics, Inc.(ITI) Clinical Trials and PubMed Articles about Immunomic Therapeutics, Inc.(ITI) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Immunomic Therapeutics, Inc.(ITI) Companies in our database. You can also find out about relevant Immunomic Therapeutics, Inc.(ITI) Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...


Corporate Database Quicklinks



Searches Linking to this Company Record